COVID-19 infections in hospital personnel

COVID-19 infections in hospital personnel - CoHo

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-004419-14-FI

Enrollment

1000

Registered

2021-09-13

Start date

2021-10-18

Completion date

Unknown

Last updated

2024-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

Trade Name: Comirnaty Pharmaceutical Form: Concentrate and solvent for suspension for injection Trade Name: Vaxzevria Pharmaceutical Form: Concentrate for solution for injection Trade Name: Spikevax

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospital personnel of Turku University Hospital, Finland, personnel who work with patients and mainly those who are at risk of COVID-19 transmission at work. Age 18-68 years. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1000 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 20

Exclusion criteria

Exclusion criteria: Iv-immunoglobulin treatment.

Design outcomes

Primary

Measure	Time frame
Main Objective: Immune response induced by Covid-19 vaccine;Secondary Objective: Among study subjects, who have received one, two or in the future possibly three or more SARS-CoV-2 -vaccinations What is the number and proportion of subjects with SARS-COV-2 specific antibody response, what is the antibody response of serological type - How long does the response last - The number of SARS-CoV-2 -infections during follow-up after vaccinations What is the number and proportion of subjects with SARS-COV-2 specific cellular immune response, what characteristics does the response present - How long does the response last - The number of SARS-CoV-2 -infections during follow-up after vaccinations ;Primary end point(s): Immune response to Covid-19 vaccines. Vaccine induced humoral and cellular immunity to COVID-19.;Timepoint(s) of evaluation of this end point: Before and 3-12 weeks after primary and secondary dose of the vaccination and every 3 months after that.	—

Measure

Time frame

Main Objective: Immune response induced by Covid-19 vaccine;Secondary Objective: Among study subjects, who have received one, two or in the future possibly three or more SARS-CoV-2 -vaccinations What is the number and proportion of subjects with SARS-COV-2 specific antibody response, what is the antibody response of serological type - How long does the response last - The number of SARS-CoV-2 -infections during follow-up after vaccinations What is the number and proportion of subjects with SARS-COV-2 specific cellular immune response, what characteristics does the response present - How long does the response last - The number of SARS-CoV-2 -infections during follow-up after vaccinations ;Primary end point(s): Immune response to Covid-19 vaccines. Vaccine induced humoral and cellular immunity to COVID-19.;Timepoint(s) of evaluation of this end point: Before and 3-12 weeks after primary and secondary dose of the vaccination and every 3 months after that.

—

Secondary

Measure	Time frame
Secondary end point(s): Immune response to Covid-19 vaccines. Vaccine induced humoral and cellular immunity to COVID-19. - Duration of the immunity - Immune response after second of further vaccination doses - Differences of immuneresponses induced by COVID-19 infection and vaccination;Timepoint(s) of evaluation of this end point: 3-12 after each vaccination and every 3 months after that.	—

Countries

Finland

Contacts

Public ContactJohanna Lempainen

Turku University Hospital

johanna.lempainen@tyks.fi+35823130000

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026